2022
A Systematic Review of Conversion to Resectability in Unresectable Metastatic Colorectal Cancer Chemotherapy Trials
Chrabaszcz S, Rajeev R, Witmer H, Dhiman A, Klooster B, Gamblin T, Banerjee A, Johnston F, Turaga K. A Systematic Review of Conversion to Resectability in Unresectable Metastatic Colorectal Cancer Chemotherapy Trials. American Journal Of Clinical Oncology 2022, 45: 366-372. PMID: 35838247, DOI: 10.1097/coc.0000000000000921.Peer-Reviewed Original ResearchConceptsMetastatic colorectal cancerUnresectable metastatic colorectal cancerOverall survivalClinical trialsPrimary outcome of OSStudy armsImproved OS of patientsConversion to resectabilitySuperior overall survivalOS of patientsSignificant survival benefitOutcomes of OSMedian survival differenceRandomized clinical trialsHigh response rateDose-effect responseMedian OSImproved OSChemotherapy trialsSurvival benefitExposure of interestPatient cohortSurvival differencesChemotherapeutic agentsColorectal cancer
2019
Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer
Sherman S, Lange J, Dahdaleh F, Rajeev R, Gamblin T, Polite B, Turaga K. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer. JAMA Oncology 2019, 5: 236-242. PMID: 30489611, PMCID: PMC6440196, DOI: 10.1001/jamaoncol.2018.5070.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCapecitabineColorectal NeoplasmsCost-Benefit AnalysisDisease ProgressionDrug CostsFemaleHumansMaintenance ChemotherapyMaleMarkov ChainsMedicareMiddle AgedModels, EconomicNeoplasm MetastasisQuality of LifeQuality-Adjusted Life YearsRandomized Controlled Trials as TopicTime FactorsTreatment OutcomeUnited StatesConceptsMetastatic colorectal cancerIncremental cost-effectiveness ratioUnresectable metastatic colorectal cancerQuality-adjusted life yearsBevacizumab maintenance therapyCost-effectiveness ratioMaintenance therapyInduction chemotherapyColorectal cancerMaintenance capecitabineStable diseaseChemotherapy cyclesCost-effectiveness of capecitabinePhase 3 randomized clinical trialIncremental costMonths of follow-upFactors affecting cost-effectivenessInfluence of capecitabineMedicare payer perspectiveProgression-free survivalMetastatic colon cancerDrug costsLife yearsPer-patient costsIncremental cost-effectiveness
2017
Cost effectiveness of maintenance bevacizumab in patients with metastatic colorectal cancer.
Lange J, Rajeev R, Gamblin T, Turaga K. Cost effectiveness of maintenance bevacizumab in patients with metastatic colorectal cancer. Journal Of Clinical Oncology 2017, 35: 718-718. DOI: 10.1200/jco.2017.35.4_suppl.718.Peer-Reviewed Original ResearchQuality adjusted life monthsMetastatic colorectal cancerMaintenance capecitabineLife monthsColorectal cancerUnresectable metastatic colorectal cancerTreatment of unresectable metastatic colorectal cancerImproved overall survivalIncremental cost-effectiveness ratioQuality of Life ScaleCost-effectiveness ratioMaintenance bevacizumabObservation armOverall survivalLife ScaleBevacizumabMaintenance armGlobal quality of life scaleTreatment strategiesCapecitabinePatientsCost-effectiveCancerEffectiveness ratioMonths
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply